Sutent Approval History
- FDA approved: Yes (First approved January 26th, 2006)
- Brand name: Sutent
- Generic name: sunitinib malate
- Company: Pfizer Inc.
- Treatment for: Gastrointestinal Stromal Tumor, Renal Cell Carcinoma, Pancreatic Cancer
Sutent (sunitinib malate) is an oral multi-kinase inhibitor indicated for the treatment of patients with gastrointestinal stromal tumors, advanced kidney cancer and pancreatic neuroendocrine tumors.
Development History and FDA Approval Process for Sutent
|May 20, 2011||FDA Approves Sutent for Rare Type of Pancreatic Cancer|
|Jan 26, 2006||Sutent Approved - Pfizer Inc. - Treatment for Gastrointestinal Stromal Tumors and Renal Carcinoma|
|Aug 10, 2005||Pfizer Submits Application for Sutent to FDA|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.